GlassScriptPhysician profile
Marshall C Bishop
NPI 1821079260
$1,953.80
in general payments reported to CMS, 2019-2025
24 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $313 · 2021: $527 · 2022: $383 · 2023: $160 · 2024: $110 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $472.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $273.07 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $182.91 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $146.14 | 2022-2025 | Mounjaro, Zepbound |
| Kowa Pharmaceuticals America, INC. | $141.41 | 2019-2024 | Livalo |
| Novartis Pharmaceuticals Corporation | $130.78 | 2019-2023 | |
| Astellas Pharma US INC | $129.92 | 2019-2022 | |
| Pfizer INC. | $127.42 | 2019-2025 | |
| Abbvie INC. | $118.81 | 2019-2021 | |
| Glaxosmithkline, LLC. | $106.27 | 2019-2021 | |
| Viatris Specialty LLC | $88.37 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $84.81 | 2019 | |
| Amarin Pharma, INC. | $78.32 | 2020-2022 | |
| Amgen INC. | $52.03 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.07 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $40.23 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $34.95 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $33.26 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $32.79 | 2025 | |
| Philips North America LLC | $27.50 | 2022-2024 | (O58) Sleep Respiratory Care Und |
| Braintree Laboratories, INC. | $24.08 | 2022 | |
| Idorsia Pharmaceuticals US INC | $20.73 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $12.39 | 2021 | |
| Genentech USA, INC. | $11.37 | 2020 | |
| Organon LLC | $5.17 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.